Evaluation of pharmacotherapy in pregnant patients with a focus on its risks and hypothetical protective factors

Objectives : Pharmacotherapy during pregnancy is considered risky and continues to be a relevant issue. This study aimed to determine how pharmacotherapy in pregnant patients influences pregnancy outcomes in clinical practice and to investigate complex and hypothetical protective factors that contribute to pregnancy outcomes. Material and methods : A retrospective observational study of pregnant patients ( n = 112) was conducted at the Department of Internal Medicine, Teaching Hospital Nitra, in Nitra, Slovak Republic, over a period of 12 years. Clinical outcomes, including the stage of pregnancy, exposure of the embryo/foetus to therapeutic agents, and pregnancy outcomes, were assessed. Results : Among the assessed patients, 82 (73%) used therapeutic agents in the first trimester; the most common use was that of a single therapeutic agent ( n = 44, 39%). Patients most frequently used therapeutic agents from group N: Nervous system ( n = 80 therapeutic agents, 25%). Notably, although half of the patients ( n = 54) used therapeutic agents during the high-risk period for malformation, more than half had healthy newborns ( n = 74, 66%). From a risk perspective, therapeutic agents classified as having no teratogenic potential but that can lead to adverse development of the embryo/foetus were predominant ( n = 92 therapeutic agents, 29%). The presence of hypothetical protective factors capable of weakening and reducing the transfer of substances, therapeutic agents, or metabolites to the embryo/foetus and lowering the potential embryotoxic/foetotoxic effects was observed in 17% of patients in the studied sample who delivered healthy neonates ( n = 76). Conclusion : Pharmacotherapy during pregnancy must be carefully considered and follow the principles of rational pharmacotherapy. Even after exposure to risky pharmacotherapy, more than half of the pregnancies resulted in healthy neonatal outcomes.

Authors

Institutions

Publication Details

Journal
Pharmacia
Published
2026-11-13
DOI
https://doi.org/10.3897/pharmacia.73.e202830
Primary Topic
Pregnancy and Medication Impact
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Evaluation of pharmacotherapy in pregnant patients with a focus on its risks and hypothetical protective factors

Mária Göböová, Kristína Podolská, Dana Mazánková
Pharmacia
Pregnancy and Medication Impact
article

Evaluation of pharmacotherapy in pregnant patients with a focus on its risks and hypothetical protective factors

Mária Göböová, Kristína Podolská, Dana Mazánková
article en

Abstract

Objectives : Pharmacotherapy during pregnancy is considered risky and continues to be a relevant issue. This study aimed to determine how pharmacotherapy in pregnant patients influences pregnancy outcomes in clinical practice and to investigate complex and hypothetical protective factors that contribute to pregnancy outcomes. Material and methods : A retrospective observational study of pregnant patients ( n = 112) was conducted at the Department of Internal Medicine, Teaching Hospital Nitra, in Nitra, Slovak Republic, over a period of 12 years. Clinical outcomes, including the stage of pregnancy, exposure of the embryo/foetus to therapeutic agents, and pregnancy outcomes, were assessed. Results : Among the assessed patients, 82 (73%) used therapeutic agents in the first trimester; the most common use was that of a single therapeutic agent ( n = 44, 39%). Patients most frequently used therapeutic agents from group N: Nervous system ( n = 80 therapeutic agents, 25%). Notably, although half of the patients ( n = 54) used therapeutic agents during the high-risk period for malformation, more than half had healthy newborns ( n = 74, 66%). From a risk perspective, therapeutic agents classified as having no teratogenic potential but that can lead to adverse development of the embryo/foetus were predominant ( n = 92 therapeutic agents, 29%). The presence of hypothetical protective factors capable of weakening and reducing the transfer of substances, therapeutic agents, or metabolites to the embryo/foetus and lowering the potential embryotoxic/foetotoxic effects was observed in 17% of patients in the studied sample who delivered healthy neonates ( n = 76). Conclusion : Pharmacotherapy during pregnancy must be carefully considered and follow the principles of rational pharmacotherapy. Even after exposure to risky pharmacotherapy, more than half of the pregnancies resulted in healthy neonatal outcomes.

PharmaciaVol. 73
Slovak University of Agriculture in Nitra (SK), Masaryk University (CZ), Constantine the Philosopher University in Nitra (SK), Animal Production Research Centre (SK)
Good health and well-being
Pregnancy and Medication Impact
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon